DeepMed Research

Oric Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 100

Market Cap: $704.7M

Website: http://www.oricpharma.com

Introduction: Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Clinical Trials

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Phase 1

Recruiting

Conditions: EGFR Exon 20 Insertion Mutations
NSCLC
Solid Tumors
EGFR-mutated NSCLC

Interventions: Drug: ORIC-114 Dose 1 + amivantamab
Drug: ORIC-114 Dose 2 + amivantamab
Drug: ORIC-114 Dose 3 + amivantamab

First Posted Date: 2025-02-10

Last Posted Date: 2025-03-20

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT06816992

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 1 locations

Effect of Food on the Pharmacokinetics of ORIC-114

Phase 1

Completed

Conditions: Food Effect in Healthy Participants

Interventions: Drug: ORIC-114

First Posted Date: 2023-08-25

Last Posted Date: 2024-01-19

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT06012721

Locations: 🇦🇺
Nucleus Network Pty Ltd., 235 Ryrie St, Geelong, Victoria, Australia
🇦🇺
Nucleus Network Pty Ltd., Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, Victoria, Australia

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Prostate Cancer

Interventions: Drug: ORIC-944
Drug: Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
Drug: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Drug: Darolutamide (Nubeqa®) 300 mg tablets
Drug: Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets

First Posted Date: 2022-06-10

Last Posted Date: 2025-03-20

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT05413421

Locations: 🇺🇸
South Florida Oncology and Hematology, Plantation, Florida, United States
🇺🇸
First Urology, Jeffersonville, Indiana, United States
🇺🇸
University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 12 locations

Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: ORIC-114
Drug: Chemotherapy drug

First Posted Date: 2022-04-07

Last Posted Date: 2024-10-18

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT05315700

Locations: 🇺🇸
City of Hope, Long Beach, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 27 locations

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: ORIC-533

First Posted Date: 2022-02-07

Last Posted Date: 2025-03-20

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT05227144

Locations: 🇨🇦
Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario, Canada
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 5 locations

Study of ORIC-101 in Combination With Enzalutamide

Phase 1

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: ORIC-101
Drug: enzalutamide 40 MG oral capsule [Xtandi]

First Posted Date: 2019-07-26

Last Posted Date: 2023-12-15

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04033328

Locations: 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of ORIC-101 in Combination With Anticancer Therapy

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: ORIC-101
Drug: Nab-paclitaxel

First Posted Date: 2019-04-26

Last Posted Date: 2023-12-15

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT03928314

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States

and more 8 locations

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ORIC-101

First Posted Date: 2019-02-08

Last Posted Date: 2019-02-08

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT03835637

Locations: 🇬🇧
Research Center, Nottingham, United Kingdom

Study of ORIC-101 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ORIC-101

First Posted Date: 2017-10-27

Last Posted Date: 2018-04-05

Lead Sponsor: ORIC Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03324555

Locations: 🇺🇸
Research Center, Miami, Florida, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy